Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swedish Orphan Biovitrum AB ( (SE:SOBI) ) just unveiled an update.
Swedish Orphan Biovitrum AB (Sobi) has completed the issuance and repurchase of class C shares to secure obligations under its long-term incentive programs. Svenska Handelsbanken AB subscribed to all issued shares, which will be converted into common shares to fulfill future commitments, increasing Sobi’s holdings to 12,756,537 common shares.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK314.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharma company focused on breakthrough innovations for rare diseases, with approximately 1,900 employees across various regions including Europe, North America, and Asia. In 2024, the company reported revenues of SEK 26 billion and is listed on Nasdaq Stockholm.
Average Trading Volume: 293,599
Technical Sentiment Signal: Hold
Current Market Cap: SEK95.96B
Learn more about SOBI stock on TipRanks’ Stock Analysis page.